Strongbridge Biopharma plc Announces Presentation at the 26th Annual Oppenheimer Healthcare Conference

DUBLIN, Ireland and TREVOSE, Pa., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) today announced that management will be presenting at the 26th Annual Oppenheimer Healthcare Conference to be held December 8 – 9, 2015 in New York City.

Matthew Pauls, president and chief executive officer of Strongbridge Biopharma, is scheduled to present on Tuesday, December 8, 2015 at 1:35 p.m. EST. The presentation will be webcast live and available on the "Events & Presentations" page in the Investor section of the Company's website at www.strongbridgebio.com.

About Strongbridge Biopharma

Strongbridge Biopharma's strategic focus is to build a biopharmaceutical company focused on the development, in-licensing, acquisition and eventual commercialization of complementary product candidates across multiple franchises that target rare diseases. Strongbridge Biopharma's lead product candidate, COR-003 (levoketoconazole), is a cortisol inhibitor that is currently being studied in the global Phase 3 trial for the treatment of endogenous Cushing's syndrome. COR-003 and COR-005 have received orphan designation from both the European Medicines Agency and the U.S. Food and Drug Administration, and the Company is pursuing orphan designation for COR-004. Strongbridge Biopharma recently expanded its rare endocrine disease franchise with the completion of transactions for two Phase 2 product candidates: COR-004, a novel second-generation antisense compound, which is in clinical development for the treatment of acromegaly and designed to block the synthesis of growth hormone receptor (GHr), thereby reducing levels of insulin-like growth factor-1 (IGF-1) in the blood; and COR-005, a next-generation somatostatin analog (SSA) with a unique receptor affinity profile, being investigated for the treatment of acromegaly, with potential additional applications in Cushing's disease and neuroendocrine tumors. Strongbridge Biopharma's intent is to independently commercialize its rare endocrine assets in key global markets.

CONTACT: Corporate and Media Relations
         Elixir Health Public Relations
         Lindsay Rocco
         +1 862-596-1304
         [email protected]

         Investor Relations
         ICR Inc.
         Stephanie Carrington
         +1 646-277-1282
         [email protected]

         USA
         900 Northbrook Drive
         Suite 200
         Trevose, PA 19053
         Tel. +1 610-254-9200
         Fax. +1 215-355-7389

Source: Strongbridge Biopharma plc

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Danone: Good start to the year; Further delivering on Renew Danone
• Surgery Partners, Inc. Announces First Quarter 2024 Earnings Release Date and Conference Call Details
• Biophytis Announces New Scientific Advisory Board for its Phase 2 OBA Clinical Study in Obesity